Subscribe
maraze-shutterstock-com
MaraZe / Shutterstock.com
21 July 2016Americas

Hikma launches generic Xeloda in the US

Hikma Pharmaceuticals announced yesterday that its US affiliate West-Ward Pharmaceuticals, has launched a generic version of Genentech’s cancer treatment drug Xeloda (capecitabine) in the US.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Hikma ‘skinny’ label does not infringe Amarin patents
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.
Africa
Hikma and Vectura collaborate to develop GSK generics
12 November 2018   Jordan-based Hikma Pharmaceuticals and British pharmaceutical company Vectura Group have united to develop generic versions of GSK’s Ellipta respiratory products.


Editor's picks

Astellas win strengthens blockbuster drug's European position
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025

Editor's picks

Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Americas
BMS blocks biosimilar version of blockbuster cancer drug in India
21 July 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Generics
Hikma ‘skinny’ label does not infringe Amarin patents
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.
Africa
Hikma and Vectura collaborate to develop GSK generics
12 November 2018   Jordan-based Hikma Pharmaceuticals and British pharmaceutical company Vectura Group have united to develop generic versions of GSK’s Ellipta respiratory products.

More on this story

Generics
Hikma ‘skinny’ label does not infringe Amarin patents
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.
Africa
Hikma and Vectura collaborate to develop GSK generics
12 November 2018   Jordan-based Hikma Pharmaceuticals and British pharmaceutical company Vectura Group have united to develop generic versions of GSK’s Ellipta respiratory products.

More features

Sandoz blocked by UK court from seeking Xarelto profits
An update on patenting in Ukraine, Russia and Eurasia
The rise of pro-NPE and patent sentiment in the US
UPC sees rising small molecule litigation with Pfizer in the hot seat
Why the Caribbean cannabis economy is ripe for IP protection
China filings push rise in patent applications in Ireland
Brain disorder medtech rivals butt heads at ITC
The right formula: Minimising the cost of chemical and pharma patents